News & Updates

AD trial: Cognitive impairment exacerbated with reduced iron in brain

14 Nov 2024 by

Brain iron-lowering therapy with deferiprone appears to do more harm than good in patients with Alzheimer's disease (AD), being associated with increased cognitive decline in a phase II study.

AD trial: Cognitive impairment exacerbated with reduced iron in brain

14 Nov 2024

Add-on atezolizumab of no benefit in HER2-positive breast cancer with brain metastases

13 Nov 2024

Using atezolizumab in addition to pertuzumab plus high-dose trastuzumab does not appear to improve central nervous system (CNS) responses in HER2-positive breast cancer patients with brain metastases, according to the results of a single-arm phase II study.

Add-on atezolizumab of no benefit in HER2-positive breast cancer with brain metastases

13 Nov 2024

Prompt DOAC therapy after stroke safe for AF patients

11 Nov 2024 by

Initiating direct oral anticoagulants (DOACs) within 4 days after an ischaemic stroke in patients with atrial fibrillation (AF) is safe and yields similar outcomes as delayed initiation, as shown in the phase 4 OPTIMAS trial.

Prompt DOAC therapy after stroke safe for AF patients

11 Nov 2024

Cognitive remediation plus electrical stimulation delays cognitive decline

11 Nov 2024

Cognitive decline in older adults with remitted major depressive disorder appears to be slower when they receive cognitive remediation plus transcranial direct current stimulation, according to a study.

Cognitive remediation plus electrical stimulation delays cognitive decline

11 Nov 2024

Tenecteplase a promising alternative to alteplase for stroke thrombolysis

10 Nov 2024 by

Intravenous thrombolysis with tenecteplase is noninferior to that with alteplase, with the functional outcome and safety profile being similar, according to the results of the ORIGINAL study.

Tenecteplase a promising alternative to alteplase for stroke thrombolysis

10 Nov 2024

Original New Drug Application Approvals by US FDA (16-31 October 2024)

07 Nov 2024

New drug applications approved by US FDA as of 16-31 October 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-31 October 2024)

07 Nov 2024

Increased risk of inflammatory CNS diseases following anti-TNF therapy for autoimmune diseases

06 Nov 2024 by

Compared with conventional therapies, exposure to tumour necrosis factor (TNF) inhibitors is associated with increased risk of inflammatory central nervous system (CNS) diseases, irrespective of background autoimmune disease or TNF inhibitor type, a recent meta-analysis has found.

Increased risk of inflammatory CNS diseases following anti-TNF therapy for autoimmune diseases

06 Nov 2024

Opioid does little to ease pain in aSAH-related headache

04 Nov 2024

Use of opioids results in small reductions in pain among adult patients with an aneurysmal subarachnoid haemorrhage (aSAH)-related headache, and higher doses do not appear to significantly boost its efficacy in relieving pain, according to a study.

Opioid does little to ease pain in aSAH-related headache

04 Nov 2024

Pregabalin relieves pain, itch in recessive dystrophic epidermolysis bullosa

03 Nov 2024

In patients with recessive dystrophic epidermolysis bullosa, treatment with pregabalin appears to substantially reduce pain and itch, according to a randomized crossover trial.

Pregabalin relieves pain, itch in recessive dystrophic epidermolysis bullosa

03 Nov 2024

Low-field MRI for HK’s first one-stop acute stroke management model

02 Nov 2024 by

Low-field 0.23T MRI technology has been introduced recently as part of the launch of Hong Kong’s first one-stop acute stroke management model, the Emergency Stroke Unit (ESU), at Prince of Wales Hospital (PWH).

Low-field MRI for HK’s first one-stop acute stroke management model

02 Nov 2024

News & Updates

Filter by Specialty:

Specialty:

AD trial: Cognitive impairment exacerbated with reduced iron in brain

AD trial: Cognitive impairment exacerbated with reduced iron in brain

Add-on atezolizumab of no benefit in HER2-positive breast cancer with brain metastases

Add-on atezolizumab of no benefit in HER2-positive breast cancer with brain metastases

Prompt DOAC therapy after stroke safe for AF patients

Prompt DOAC therapy after stroke safe for AF patients

Cognitive remediation plus electrical stimulation delays cognitive decline

Cognitive remediation plus electrical stimulation delays cognitive decline

Tenecteplase a promising alternative to alteplase for stroke thrombolysis

Tenecteplase a promising alternative to alteplase for stroke thrombolysis

Original New Drug Application Approvals by US FDA (16-31 October 2024)

Original New Drug Application Approvals by US FDA (16-31 October 2024)

Increased risk of inflammatory CNS diseases following anti-TNF therapy for autoimmune diseases

Increased risk of inflammatory CNS diseases following anti-TNF therapy for autoimmune diseases

Opioid does little to ease pain in aSAH-related headache

Opioid does little to ease pain in aSAH-related headache

Pregabalin relieves pain, itch in recessive dystrophic epidermolysis bullosa

Pregabalin relieves pain, itch in recessive dystrophic epidermolysis bullosa

Low-field MRI for HK’s first one-stop acute stroke management model

Low-field MRI for HK’s first one-stop acute stroke management model